Clinical trial
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00016094 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016094 |
|---|---|
| Title | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Bevacizumab (rhuMab VEGF) (NSC-704865) Therapy for Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Biological, Other |
| Interventions | bevacizumab, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Apr 1, 2001 |
| Primary completion | Aug 1, 2005 |
| Completion | Sep 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 29, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: